EGFR and non-small cell lung carcinoma: Targeted therapy is currently considered the established standard-of-care for patients diagnosed with advanced-stage non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) driver mutations, which are the most commonly observed gene mutations in this type of cancer1,2.